Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Effective surveillance of adverse events following immunization (AEFIs) primarily relies on the collaboration of two partners: national regulatory authorities (NRAs) and national expanded programs on immunization (EPIs). In December 2020, the World Health Organization (WHO) Global Advisory Committee for Vaccine Safety recommended a new case-based indicator of national capacity to monitor immunization safety: at least one serious AEFI reported per 1 million total population per year. To achieve this indicator, WHO-affiliated countries and territories (WHO countries) rely upon data generated from functional AEFI surveillance systems. This report describes 2020-2022 global, regional, and national progress in use of the newly introduced immunization safety monitoring indicator and progress on joint AEFI reporting from national EPIs and NRAs. Among WHO countries, 51 (24%) of 214 implemented the new indicator in 2020, 111 (52%) of 214 implemented it in 2021, and 92 (43%) of 215 in 2022. In 2020, 41 (19%) WHO countries reported AEFI data jointly from EPIs and NRAs; this increased to 55 (26%) in 2021 and 57 (27%) in 2022. These findings, resulting in part from the intensified support for COVID-19 vaccination, demonstrate that national AEFI surveillance systems increasingly support the timely use and sharing of case-based immunization safety data, but work is still needed to strengthen global vaccine safety monitoring.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715821PMC
http://dx.doi.org/10.15585/mmwr.mm7249a2DOI Listing

Publication Analysis

Top Keywords

immunization safety
16
safety monitoring
12
vaccine safety
8
aefi surveillance
8
surveillance systems
8
epis nras
8
214 implemented
8
safety
6
national
6
immunization
5

Similar Publications

The emergence of messenger ribonucleic acid (mRNA) vaccines as an alternative platform to traditional vaccines has been accompanied by advances in nanobiotechnology, which have improved the stability and delivery of these vaccines through novel nanoparticles (NPs). Specifically, the development of NPs for mRNA delivery has facilitated the loading, protection and release of mRNA in the biological microenvironment, leading to the stimulation of mRNA translation for effective intervention strategies. Intriguingly, two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), have been permitted for emergency usage authorization to prevent COVID-19 infection by USFDA.

View Article and Find Full Text PDF

This research emphasized the extraction and separation of polysaccharides derived from Syzygium jambos (L.) Alston (PSJAP-5), as well as analyses of their structural characteristics and immunomodulatory activities. This study initially employed response surface methodology to determine the extraction conditions of polysaccharides.

View Article and Find Full Text PDF

Leveraging dietary fiber's natural physiology: from dietary insights to nanoscale IBD intervention.

Crit Rev Food Sci Nutr

September 2025

Food Safety Key Laboratory of Zhejiang Province, School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, China.

The prevalence of inflammatory bowel disease (IBD), including crohn's disease and ulcerative colitis, is rising worldwide. Among various potential contributors, low dietary fiber (DF) diet habit stands out as a substantial factor in this accelerating trend. Conversely, DF supplementation inhibits the manifestation of IBD pathology and promotes inflammatory remission.

View Article and Find Full Text PDF

A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer.

J Vis Exp

August 2025

Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa; Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa; Geminii, Inc.

Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease.

View Article and Find Full Text PDF

Purpose: Varlilumab is a CD27 agonist antibody, delivering a T-cell costimulation. Preclinical studies show agonistic CD27 antibodies can activate intratumoral T-cells to release chemokines and cytokines to augment macrophage-dependent tumor killing induced by CD20 antibodies, i.e.

View Article and Find Full Text PDF